SAN DIEGO, April 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it has filed a marketing application in Europe for Vitaros ® as a treatment ...

Apricus Biosciences announced that the company has filed its response to questions received from Swissmedic, the Agency for Therapeutic Products in Switzerland, relating to its marketing application ...

SAN DIEGO, May 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file a marketing application in Switzerland for Vitaros ® as a ...

SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its ...

My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about APRI -- Potential Market Size for Vitaros® for Erectile Dysfunction in ...

announced today its filing of a marketing application for Vitaros as a treatment for patients with erectile dysfunction in Switzerland, with Swissmedic, the Swiss Agency for Therapeutic Products. "We ...

Shares of Apricus Biosciences, Inc.APRI surged almost 90% after the company announced that its topical cream Vitaros was approved in Mexico for the treatment of patients with erectile dysfunction.

Apricus Biosciences, Inc. APRI, a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Ministry of ...

The Company has one approved product, Vitaros (R), for the treatment of erectile dysfunction, which is now approved in Europe and Canada and will be commercialized by Apricus Bio's marketing partners ...

Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...